Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
Ozempic is classified as a glucagon-like peptide-1 (GLP-1) agonist
With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability [1][4]
Hypocalcemia is most commonly seen within the first six months of GLP-1 receptor agonist therapy, while hypercalcemia is noted to occur after at least six months of therapy
Yes, most patients transition between these medications without any issues
Longuet C, et al
Table 4: Glycemic Parameters at Final Visit (24-Week Study) of Sitagliptin in Add-on Combination Therapy with Metformin* Sitagliptin Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled on the Combination of Metformin and Glimepiride A total of 441 patients with type 2 diabetes participated in a 24-week, randomized, double-blind, placebo-controlled study designed to assess the efficacy of sitagliptin in combination with glimepiride, with or without metformin
US$ 25.07
US$ 24.66
US$ 28.16
US$ 23.92
US$ 26.43
US$ 23.50
US$ 27.18
US$ 25.09
US$ 26.06
US$ 25.92
US$ 27.54
